Bellacasa

Aquamer Medical was a clinical-stage biotechnology and medical device company focused on developing water-based tissue-bulking products for applications in gastroenterology, urology, and dermatology. The company's lead product candidate, AquaFlux, was designed as a minimally invasive injectable bulking agent for the treatment of chronic heartburn and gastroesophageal reflux disease (GERD). Its platform technology utilized proprietary hydrogel formulations to provide structural support and tissue augmentation. Historically, the company was involved in a complex corporate restructuring involving Bellacasa Productions, which served as its parent entity before spinning off the medical assets. Aquamer Medical is no longer active as an independent entity.